Literature DB >> 22423260

Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.

Theodoros Kelesidis1, Charalabos Pothoulakis.   

Abstract

Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanisms of action of S. boulardii and its properties may explain its efficacy and beneficial effects in acute and chronic gastrointestinal diseases that have been confirmed by clinical trials. Caution should be taken in patients with risk factors for adverse events. This review discusses the evidence for efficacy and safety of S. boulardii as a probiotic for the prevention and therapy of gastrointestinal disorders in humans.

Entities:  

Keywords:  Saccharomyces boulardii; efficacy; gastrointestinal disorders; probiotic; safety

Year:  2012        PMID： 22423260      PMCID： PMC3296087          DOI： 10.1177/1756283X11428502

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.802


  124 in total

Review 1.  Clinical practice. Antibiotic-associated diarrhea.

Authors:  John G Bartlett
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

2.  Evaluation of deficiencies in labeling of commercial probiotics.

Authors:  J Scott Weese
Journal:  Can Vet J       Date:  2003-12       Impact factor: 1.008

3.  Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis.

Authors:  Mario Guslandi
Journal:  J Clin Gastroenterol       Date:  2010 May-Jun       Impact factor: 3.062

4.  Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children.

Authors:  David Gaón; Hugo García; Luis Winter; Nora Rodríguez; Ricardo Quintás; Silvia N González; Guillermo Oliver
Journal:  Medicina (B Aires)       Date:  2003       Impact factor: 0.653

5.  Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events.

Authors:  Karen L Mumy; Xinhua Chen; Ciarán P Kelly; Beth A McCormick
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-11-21       Impact factor: 4.052

6.  Clinical efficacy of Saccharomyces boulardii and metronidazole compared to metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study.

Authors:  Ener C Dinleyici; Makbule Eren; Zeynel A Yargic; Nihal Dogan; Yvan Vandenplas
Journal:  Am J Trop Med Hyg       Date:  2009-06       Impact factor: 2.345

7.  Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines.

Authors:  J P Buts; N De Keyser; L De Raedemaeker
Journal:  Pediatr Res       Date:  1994-10       Impact factor: 3.756

8.  Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii.

Authors:  J P Buts; P Bernasconi; J P Vaerman; C Dive
Journal:  Dig Dis Sci       Date:  1990-02       Impact factor: 3.199

9.  Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study.

Authors:  Khin Htwe; Khin Saw Yee; Marlar Tin; Yvan Vandenplas
Journal:  Am J Trop Med Hyg       Date:  2008-02       Impact factor: 2.345

10.  Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies.

Authors:  Neha Pant; Harold Marcotte; Harald Brüssow; Lennart Svensson; Lennart Hammarström
Journal:  BMC Microbiol       Date:  2007-09-27       Impact factor: 3.605
View more
  80 in total

1.  Effects of Probiotic Lactobacillus acidophilus Strain INMIA 9602 Er 317/402 and Putative Probiotic Lactobacilli on DNA Damages in the Small Intestine of Wistar Rats In Vivo.

Authors:  Astghik Z Pepoyan; Marine H Balayan; Lilit Malkhasyan; Anahit Manvelyan; Tatevik Bezhanyan; Ruzanna Paronikyan; Vardan V Tsaturyan; Stepan Tatikyan; Shigeru Kamiya; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2019-09       Impact factor: 4.609

Review 2.  Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases?

Authors:  John Heineman; Sara Bubenik; Stephen McClave; Robert Martindale
Journal:  Curr Gastroenterol Rep       Date:  2012-08

Review 3.  Probiotics, prebiotics and synbiotics- a review.

Authors:  Kavita R Pandey; Suresh R Naik; Babu V Vakil
Journal:  J Food Sci Technol       Date:  2015-07-22       Impact factor: 2.701

Review 4.  Production and Biomedical Applications of Probiotic Biosurfactants.

Authors:  Anila Fariq; Ayesha Saeed
Journal:  Curr Microbiol       Date:  2016-01-07       Impact factor: 2.188

5.  Synergistic effects of fenbendazole and metronidazole against Giardia muris in Swiss mice naturally infected.

Authors:  Renata Coltro Bezagio; Cristiane Maria Colli; Liara Izabela Lopes Romera; Érika Cristina Ferreira; Ana Lúcia Falavigna-Guilherme; Mônica Lúcia Gomes
Journal:  Parasitol Res       Date:  2016-12-30       Impact factor: 2.289

6.  Letters to the editor.

Authors: 
Journal:  Ochsner J       Date:  2012

Review 7.  Recent innovations in the production of selected specialty (non-traditional) beers.

Authors:  Pradeep Puligundla; Daniela Smogrovicova; Chulkyoon Mok
Journal:  Folia Microbiol (Praha)       Date:  2021-06-07       Impact factor: 2.099

8.  PrimiOtic and PrimiOtic Plus: novel probiotic for primates suffering from idiopathic chronic diarrhea.

Authors:  Jaime L Lecker; Karen Froberg-Fejko
Journal:  Lab Anim (NY)       Date:  2015-10       Impact factor: 12.625

9.  Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis.

Authors:  Grettel García-Collinot; Eduardo Osiris Madrigal-Santillán; Michel A Martínez-Bencomo; Rosa A Carranza-Muleiro; Luis J Jara; Olga Vera-Lastra; Daniel H Montes-Cortes; Gabriela Medina; María Pilar Cruz-Domínguez
Journal:  Dig Dis Sci       Date:  2019-09-23       Impact factor: 3.199

Review 10.  A review of the economics of treating Clostridium difficile infection.

Authors:  Kari A Mergenhagen; Amy L Wojciechowski; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.